Quantcast

Latest Adenoviridae Stories

2010-11-19 08:00:00

RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2010 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Piper Jaffray 22nd Annual Health Care Conference on December 1, 2010 at 11:50 a.m. ET in New York City. Mr. Moch will give an update on the company's pipeline and technology assets, including CMX001, a...

2010-11-17 08:00:00

GENEVA and RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2010 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented an update to the World Health Organization (WHO) on the development of the company's lead antiviral compound, CMX001, at the 12th Meeting of the WHO Advisory Committee on Variola Virus Research in a presentation titled "Status of CMX001 for Smallpox and Other dsDNA Viruses." CMX001 is being developed for...

2010-11-10 09:37:00

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2010 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Lazard Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17, 2010, 10:30 a.m. ET, at the St. Regis hotel in New York City. Mr. Moch will give an update on the company's pipeline and...

2010-11-09 12:08:00

AMSTERDAM, and RESEARCH TRIANGLE PARK, N.C., Nov. 9, 2010 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced that data supportive of the company's lead Phase 2 antiviral compound CMX001 were presented today during a late-breaker session by Hans H. Hirsch, MD, MSc, Professor of Clinical Virology, Division of Infectious Diseases, University of Basel, Switzerland, at the Antiviral Congress 2010 being held in Amsterdam, The...

2010-10-22 07:45:00

VANCOUVER, British Columbia and RESEARCH TRIANGLE PARK, N.C., Oct. 22 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, will present promising clinical data for CMX001 in a late-breaker poster session at the Infectious Diseases Society of America (IDSA) 48th Annual Meeting. Data from immunocompromised patients infected with adenovirus and treated with oral CMX001 demonstrated a significant drop in viral load compared to...

2010-09-28 10:51:00

RESEARCH TRIANGLE PARK, N.C., Sept. 28 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present a corporate overview at the upcoming BIO Investor Forum Conference on October 5th, 2010 at 2:00pm PT. The conference is being held at the Palace Hotel in San Francisco, California. Mr. Moch will discuss the company's antiviral pipeline and technology...

2010-09-21 09:33:28

(Ivanhoe Newswire) -- Could virus cause obesity? New research shows having one particular virus -- known as adenovirus 36 (AD36) -- may increase a child's risk of becoming obese. Researchers from the University of California, San Diego School of Medicine tested 124 children who were between ages 8 and 18 for AD36 -- one of more than 50 strains of the adenovirus, which is known to cause respiratory, gastrointestinal and other infections. AD36 is the only human adenovirus currently linked to...

9f92928fc4dfefae560adb6992eed49f1
2010-09-20 09:30:00

New research, published in the September 20 online edition of the journal Pediatrics, suggests that a virus that causes respiratory infections could also be a trigger for childhood obesity. Researchers, including University of California, San Diego (UC San Diego) Associate Professor of Clinical Pediatrics Jeffery B. Schwimmer, studied 124 children ranging from eight to 18-years of age. Specifically, according to a UC San Diego press release, they were searching for "the presence of antibodies...

2010-09-17 08:15:00

RESEARCH TRIANGLE PARK, N.C., Sept. 17 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present a corporate overview at the upcoming 12th Annual UBS Global Life Sciences Conference on September 22, 2010 at 3:30 pm ET. The conference is being held at the Grand Hyatt in New York City. Mr. Moch will discuss the company's antiviral pipeline and...

0e3eb0f689d5bf454af3a5fc0d8032e3
2010-09-01 20:27:15

Researchers clear hurdle on path toward gene-therapy treatment for diseaseOne of the most difficult aspects of working at the nanoscale is actually seeing the object being worked on. Biological structures like viruses, which are smaller than the wavelength of light, are invisible to standard optical microscopes and difficult to capture in their native form with other imaging techniques. A multidisciplinary research group at UCLA has now teamed up to not only visualize a virus but to use...


Latest Adenoviridae Reference Libraries

0_f9fe10c6664d20ba0d9091907b66a65f
2011-01-05 16:00:36

Human parainfluenza viruses, belonging to the paramyxovirus family, are a group of four distinct serotypes of enveloped single-stranded RNA viruses. They are the second most common cause of lower respiratory tract infection in younger children. Many times the host has repeat infections throughout life with symptoms that may include upper respiratory tract illness or more commonly, a cold and sore throat. It can also cause severe pneumonia in immunosuppressed people. There is currently no...

More Articles (1 articles) »
Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related